Table 5.
Treatments received in HER2-positive BCP diagnosed during first trimester versus HER2 BCP diagnosed during second and third trimester.
| HER2-positive BCP First Trimester (n = 14) | HER2 BCP Second and third Trimester (n = 34) | p | |
|---|---|---|---|
| Chemotherapy, n(%) Neoadjuvant Adjuvant | 6 (43) 8 (57) | 28 (82) 6 (18) | 0.01 |
| Chemotherapy modalities received during pregnancy, n(%) | n = 10 patients | n = 29 patients | |
| 1 AC | 0 (0) | 2 (7) | 0.06 |
| 2 AC | 0 (0) | 6 (21) | |
| 3 AC | 1 (10) | 6 (21) | |
| 4 AC | 0 (0) | 6 (21) | |
| 4 AC + 1 taxol | 0 (0) | 1 (3) | |
| 4 AC + 2 taxol | 4 (40) | 4 (14) | |
| 4 AC + 3 taxol | 2 (20) | 1 (3) | |
| 4 AC + 4 taxol | 0 (0) | 0 (0) | |
| Missing data | 3 (30) | 3 (10) | |
| Total only AC | 1 (10) | 20 (70) | 0.004 |
| Total AC + taxol | 6 (60) | 6 (20) | |
| Surgery during pregnancy∗, n(%) | 7 (50) | 5 (15) | 0.02 |
| Mammary surgery, n(%) | |||
| Partial mastectomy | 5 (36) | 11 (32) | 1 |
| Total mastectomy | 8 (57) | 19 (56) | |
| None | 1 (7) | 4 (12) | |
| Axillary surgery, n(%) | |||
| Sentinel lymph node (SLN) | 5 (36) | 8 (24) | 0.33 |
| Lymphadenectomy | 8 (57) | 20 (59) | |
| None | 1 (7) | 6 (18) | |
| Post-operative radiotherapy, n(%) | 11 (79)∗∗ | 31 (91) | 0.33 |
| Antihormonal treatment, n(%) | 11 (79) | 20 (59) | 0.32 |
AC: anthracyclines.
∗first surgery, before chemotherapy.
∗∗ post-partum radiotherapy.